Value of Heart Rate Lowering Therapy in Acute Myocarditis
NCT06312891 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2024-03-15
Summary
To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.
Conditions
Interventions
- DRUG
-
Ivabradine
heart rate lowering therapy
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-01
- Primary Completion
- 2025-04-01
- Completion
- 2025-06-01
- FDA Drug
- Yes
Countries
- Egypt
Study Locations
More Related Trials
-
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
NCT05594342 ·Status: UNKNOWN ·Phase: PHASE3
-
Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine
NCT01373619 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome
NCT00815100 ·Status: COMPLETED ·Phase: PHASE4
-
Ivabradine for Rate Control in Permanent Atrial Fibrillation
NCT03987204 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
NCT00202579 ·Status: COMPLETED ·Phase: PHASE2
-
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction
NCT02053493 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
NCT03387605 ·Status: UNKNOWN ·Phase: PHASE4
-
Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy
NCT02166060 ·Status: UNKNOWN ·Phase: PHASE4
-
Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes
NCT03631654 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
NCT05961202 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Heart Rate Reduction in Heart Failure
NCT01178528 ·Status: COMPLETED ·Phase: PHASE3
-
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
NCT03650205 ·Status: UNKNOWN ·Phase: NA
-
Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention
NCT04632121 ·Status: UNKNOWN
-
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
NCT02441218 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome
NCT05536271 ·Status: COMPLETED ·Phase: PHASE2
-
Early Administration of Ivabradine in Children With Heart Failure
NCT04405804 ·Status: UNKNOWN ·Phase: PHASE2
-
Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS
NCT05536284 ·Status: COMPLETED ·Phase: PHASE2
-
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
NCT06853951 ·Status: RECRUITING ·Phase: PHASE3
-
Ivabradine and Post-revascularisation Microcirculatory Dysfunction
NCT02507050 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
NCT02446990 ·Status: COMPLETED ·Phase: PHASE3
-
If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure
NCT00757055 ·Status: WITHDRAWN ·Phase: PHASE2
-
Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction
NCT02046044 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction
NCT06964607 ·Status: COMPLETED
-
Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure
NCT02236247 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.
NCT06276127 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3